Conservation of Structure, Signaling and Pharmacology Between Two Serotonin Receptor Subtypes from Decapod Crustaceans, Panulirus Interruptus and Procambarus Clarkii

Total Page:16

File Type:pdf, Size:1020Kb

Load more

92 The Journal of Experimental Biology 211, 92-105 Published by The Company of Biologists 2008 doi:10.1242/jeb.012450 Conservation of structure, signaling and pharmacology between two serotonin receptor subtypes from decapod crustaceans, Panulirus interruptus and Procambarus clarkii Nadja Spitzer*, Donald H. Edwards and Deborah J. Baro† Department of Biology, Georgia State University, Atlanta, GA 30302, USA *Present address: 219 BBSC, Department of Biology, College of Science, Marshall University, 1 John Marshall Drive, Huntington, WV 25755, USA †Author for correspondence (e-mail: [email protected]) Accepted 25 October 2007 SUMMARY Serotonin (5-HT) plays important roles in the maintenance and modulation of neural systems throughout the animal kingdom. The actions of 5-HT have been well characterized for several crustacean model circuits; however, a dissection of the serotonergic transduction cascades operating in these models has been hampered by the lack of pharmacological tools for invertebrate receptors. Here we provide pharmacological profiles for two 5-HT receptors from the swamp crayfish, Procambarus clarkii: 5-HT2␤ and 5-HT1␣. In so doing, we also report the first functional expression of a crustacean 5-HT1 receptor, and show that it inhibits accumulation of cAMP. The drugs mCPP and quipazine are 5-HT1␣ agonists and are ineffective at 5-HT2␤. Conversely, methiothepin and cinanserin are antagonists of 5-HT2␤ but do not block 5-HT1␣. A comparison of these two receptors with their orthologs from the California spiny lobster, Panulirus interruptus, indicates conservation of protein structure, signaling and pharmacology. This conservation extends beyond crustacean infraorders. The signature residues that form the ligand-binding pocket in mammalian 5-HT receptors are found in the crustacean receptors. Similarly, the protein domains involved in G protein coupling are conserved between the two crustacean receptors and other characterized arthropod and mammalian 5-HT receptors. Considering the apparent conservation of pharmacological properties between crustacean 5-HT receptors, these tools could be applicable to related crustacean physiological preparations. Key words: agonist, antagonist, neuromodulation, G protein-coupled receptor, amine, cloning. INTRODUCTION of these receptors might change in response to social or Serotonin (5-HT) is an important neurotransmitter and environmental stimuli. neurohormone in most animal species. Diverse processes, including Crustacean hormonal circuits with small numbers of identifiable social behaviors and a variety of systemic physiological functions cells are ideal preparations for investigating the mechanistic basis are regulated by this biogenic amine. Animals have evolved a suite of modulation and plasticity. Such studies have, however, been of 5-HT receptor types; thus, a single neurotransmitter can have limited by the lack of pharmacological tools. Although the protein multiple and complex effects on different tissues. To date, seven sequences and second-messenger couplings of 5-HT receptors are classes of serotonin receptors have been identified in mammals. relatively well conserved across all species, their pharmacological These receptor classes are categorized with respect to their signal profiles can vary significantly between vertebrate and invertebrate transduction mechanisms and pharmacological properties preparations, and even within invertebrate preparations (Tierney, (Gerhardt and van Heerikhuizen, 1997; Hoyer et al., 2002; Kroeze 2001). This is not surprising as one would not expect selection for et al., 2002). or against amino acids involved in binding synthetic ligands. We In invertebrate nervous systems 5-HT can modulate motor have recently identified and cloned two crustacean 5-HT receptors pattern generation (Hooper and DiCaprio, 2004), escape and social from the spiny lobster, Panulirus interruptus, infraorder Achelata: status (Edwards et al., 1999), aggression (Kravitz, 2000) and 5-HT1␣Pan and 5-HT2␤Pan (Clark et al., 2004; Sosa et al., 2004). We learning (Barbas et al., 2003; Bicker, 1999; Kandel and Schwartz, were interested to know whether the actions of pharmacological 1982). Serotonin has multiple and complex roles in crustacean agents were conserved across crustacean species. We therefore models. 5-HT application to the stomatogastric nervous system of obtained full-length clones for the same two receptors from a decapod crustaceans elicits distinct responses from individual second distantly related decapod crustacean, the swamp crayfish, identified neurons (Flamm and Harris-Warrick, 1986), and these Procambarus clarkii (infraorder Astacidea), and expressed these responses can differ for the same identified neuron in different receptors in a heterologous system in order to determine their species (Katz and Tazaki, 1992). In the crayfish, the social status second messenger couplings and pharmacological profiles. These of an individual determines the directionality of 5-HT modulation parameters were then compared across the two species. of the lateral giant escape circuit response to sensory stimulation (Yeh et al., 1997; Yeh et al., 1996). The rate and concentration of MATERIALS AND METHODS 5-HT application to the circuit also affect this response (Teshiba et Animals al., 2001). These studies suggest that crustaceans express several Crayfish, Procambarus clarkii Girard 1852, were obtained from different 5-HT receptor types and that the expression or signaling Atchafalaya Biological Supply (Raceland, LA, USA) and kept Conservation of crustacean 5-HT receptors 93 communally at 20°C in 40·l tanks with continual filtration and Sequence data were analyzed using Sequencher 4.1 (Gene Codes aeration. Corp., Ann Arbor, MI, USA). Sequences for other arthropod species were obtained from GenBank and alignments were created Chemicals and cell lines to determine sequence identities using the ClustalW algorithm with HEK293, NIH3T3, COS-7 and MDCK cells, Earle’s minimal default settings in Lasergene MegAlign (DNASTAR Inc., essential medium (EMEM), horse serum, trypsin, penicillin and Madison, WI, USA). Full Procambarus sequences have been streptomycin were obtained from the American Type Culture deposited in GenBank under accession numbers EU131666 (5- Collection (Mannassas, VA, USA). Dulbecco’s modified Eagle’s HT2␤Pro) and EU131667 (5-HT1␣Pro). medium (DMEM) was from Mediatech Inc. (Herndon, VA, USA). Dialyzed fetal bovine serum (FBS), TRex cell line (293-TR), Generation of cell cultures expressing crustacean 5-HT pDNA4/TO plasmid, blasticidin and zeocin were from Invitrogen receptors (Carlsbad, CA, USA). Cinanserin was obtained from Tocris We previously characterized the signaling and pharmacological (Ballwin, MO, USA). All other chemicals were from Sigma (St properties of the 5-HT2␤Pan receptor transiently expressed in Louis, MO, USA). For pharmacology experiments, amine and HEK293 cells (Clark et al., 2004). We used the same techniques to –1 –1 agonist stock solutions (10 ·mol·l ) were made fresh for every characterize the Procambarus ortholog, 5-HT2␤Pro. Briefly, cells experiment in medium or 50% ethanol, respectively. Two were maintained in EMEM supplemented with 10% FBS, exceptions were tyramine (Tyr), which was made fresh as a 50·i.u.·ml–1 penicillin and 50·␮g·ml–1 streptomycin (normal 10–2·mol·l–1 stock in medium, and methysergide, which was made medium). Cells were plated on 60·mm dishes in EMEM without as a 10–2·mol·l–1 stock in DMSO and stored at –20°C. Antagonist antibiotics, allowed to grow to 95–100% confluency and then drugs were made as 10–2·mol·l–1 stock solutions in DMSO and transfected with 2·␮g of DNA using lipofectamine (Invitrogen). stored at –20°C. The plates were supplemented to a final concentration of 10% FBS 6·h after transfection, and the medium was replaced with normal Cloning of full-length 5-HT1␣ and 5-HT2␤ from Procambarus medium 24·h after transfection. clarkii and generation of expression constructs In order to functionally characterize 5-HT1␣Pan and 5-HT1␣Pro, Complete cloning and sequencing of 5-HT2␤Pan and 5-HT1␣Pan from we first generated full-length constructs using standard Panulirus interruptus have been previously described (Clark et al., recombinant techniques, as described above. The 5-HT1␣ receptors 2004; Sosa et al., 2004). were first cloned into pIRESneo and stably transfected into several We also previously cloned a large segment of 5-HT1␣Pro spanning cell lines using lipofectamine as detailed in the Results. transmembrane domains III–VII from Procambarus clarkii (Sosa et Immunoblotting experiments coupled with the lack of growth after al., 2004). We have now completed the sequencing of the 5-HT1␣Pro several weeks of selection suggested that none of these cell lines cDNA using rapid amplification of DNA ends (SMART RACE could stably express either the 5-HT1␣Pan or the 5-HT1␣Pro receptor. cDNA Amplification kit; BD Biosciences, Clontech, Cambridge, This did not appear to be a general phenomenon associated with UK) as previously described (Clark et al., 2004). Constructs crustacean receptors, as we successfully expressed 5HT2␤ receptors containing the complete ORF were assembled using standard and crustacean dopamine receptors in these cell lines. The most procedures (Ausubel et al., 1990). Both strands of the construct were reasonable explanation for our finding was that the cell lines could sequenced and errors that had been introduced in the cloning process not tolerate high levels of the 5-HT1␣ receptor, and for reasons were
Recommended publications
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • 4 Supplementary File

    4 Supplementary File

    Supplemental Material for High-throughput screening discovers anti-fibrotic properties of Haloperidol by hindering myofibroblast activation Michael Rehman1, Simone Vodret1, Luca Braga2, Corrado Guarnaccia3, Fulvio Celsi4, Giulia Rossetti5, Valentina Martinelli2, Tiziana Battini1, Carlin Long2, Kristina Vukusic1, Tea Kocijan1, Chiara Collesi2,6, Nadja Ring1, Natasa Skoko3, Mauro Giacca2,6, Giannino Del Sal7,8, Marco Confalonieri6, Marcello Raspa9, Alessandro Marcello10, Michael P. Myers11, Sergio Crovella3, Paolo Carloni5, Serena Zacchigna1,6 1Cardiovascular Biology, 2Molecular Medicine, 3Biotechnology Development, 10Molecular Virology, and 11Protein Networks Laboratories, International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 34149, Trieste, Italy 4Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy 5Computational Biomedicine Section, Institute of Advanced Simulation IAS-5 and Institute of Neuroscience and Medicine INM-9, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany 6Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy 7National Laboratory CIB, Area Science Park Padriciano, Trieste, 34149, Italy 8Department of Life Sciences, University of Trieste, Trieste, 34127, Italy 9Consiglio Nazionale delle Ricerche (IBCN), CNR-Campus International Development (EMMA- INFRAFRONTIER-IMPC), Rome, Italy This PDF file includes: Supplementary Methods Supplementary References Supplementary Figures with legends 1 – 18 Supplementary Tables with legends 1 – 5 Supplementary Movie legends 1, 2 Supplementary Methods Cell culture Primary murine fibroblasts were isolated from skin, lung, kidney and hearts of adult CD1, C57BL/6 or aSMA-RFP/COLL-EGFP mice (1) by mechanical and enzymatic tissue digestion. Briefly, tissue was chopped in small chunks that were digested using a mixture of enzymes (Miltenyi Biotec, 130- 098-305) for 1 hour at 37°C with mechanical dissociation followed by filtration through a 70 µm cell strainer and centrifugation.
  • WO 2012/068516 A2 24 May 20 12 (24.05.2012) W P O P C T

    WO 2012/068516 A2 24 May 20 12 (24.05.2012) W P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/068516 A2 24 May 20 12 (24.05.2012) W P O P C T (51) International Patent Classification: (72) Inventors; and A61K 31/352 (2006.01) A61P 25/24 (2006.01) (75) Inventors/Applicants (for US only): LETENDRE, Peter A61K 9/48 (2006.01) A61P 25/22 (2006.01) [US/US]; 2389 Indian Peaks Trail, Lafayette, Colorado A61K 9/20 (2006.01) A61P 25/00 (2006.01) 80026 (US). CARLEY, David [US/US]; 2457 Pioneer Rd., Evanston, Illinois 60201 (US). (21) International Application Number: PCT/US201 1/061490 (74) Agents: FEDDE, Kenton et al; 18325 AUenton Woods Ct, Wildwood, Missouri 63069 (US). (22) International Filing Date: 18 November 201 1 (18.1 1.201 1) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (25) Language: English Filing AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (26) Publication Language: English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (30) Priority Data: HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, 61/415,33 1 18 November 2010 (18. 11.2010) US KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (71) Applicant (for all designated States except US): PIER MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PHARMACEUTICALS [US/US]; 901 Front St., Suite OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, 201, Louisville, Colorado 80027 (US).
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
  • Customs Tariff - Schedule

    Customs Tariff - Schedule

    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
  • The Effect of Chronically Administered Lsd on the Serotonergic Nervous System of the Rat

    The Effect of Chronically Administered Lsd on the Serotonergic Nervous System of the Rat

    University of Rhode Island DigitalCommons@URI Open Access Master's Theses 1983 THE EFFECT OF CHRONICALLY ADMINISTERED LSD ON THE SEROTONERGIC NERVOUS SYSTEM OF THE RAT Bruce E. Fishman University of Rhode Island Follow this and additional works at: https://digitalcommons.uri.edu/theses Recommended Citation Fishman, Bruce E., "THE EFFECT OF CHRONICALLY ADMINISTERED LSD ON THE SEROTONERGIC NERVOUS SYSTEM OF THE RAT" (1983). Open Access Master's Theses. Paper 192. https://digitalcommons.uri.edu/theses/192 This Thesis is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Open Access Master's Theses by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. THE EFFECT OF CHRONICALLY ADMINISTERED LSD ON THE SEROTONERGIC NERVOUS SYSTEM OF THE RAT by Bruce E. Fishman A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science in Pharmacology and Toxicology UNIVERSITY OF RHODE ISLAND 1~3 ' .. MASTER OF SCIENCE DISSERTATION OF BRUCE E. FISHMAN Approved: Dissertation Committee Major Professor /~ Pmte+~ t!.i'. ~ UNIVERSITY OF RHODE ISLAND 1983 ABSTRACT Legitimate and illegitimate use of lysergic acid diethylanide (LSD) increased dramatically in the 1960 1 s. Since then, a number of studies have shown that LSD induces -psychotic symptoms in the user, suggesting a possible correlation between exposure to LSD and certain psychoses. This hypothesis is supported by repeated observations that LSD inhibits 5-HT systems in the brain and that central 5-HT systems may be implicated in certain psychoses. The present study was designed to test the hypoth­ esis that chronic administration of LSD to rats has an observable effect on 5-HT neuronal functioning in the brain.
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev

    PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev

    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0161324 A1 Johansen Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2008/0161324 A1 Johansen Et Al

    US 2008O161324A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0161324 A1 Johansen et al. (43) Pub. Date: Jul. 3, 2008 (54) COMPOSITIONS AND METHODS FOR Publication Classification TREATMENT OF VRAL DISEASES (51) Int. Cl. (76) Inventors: Lisa M. Johansen, Belmont, MA A63/495 (2006.01) (US); Christopher M. Owens, A63L/35 (2006.01) Cambridge, MA (US); Christina CI2O I/68 (2006.01) Mawhinney, Jamaica Plain, MA A63L/404 (2006.01) (US); Todd W. Chappell, Boston, A63L/35 (2006.01) MA (US); Alexander T. Brown, A63/4965 (2006.01) Watertown, MA (US); Michael G. A6II 3L/21 (2006.01) Frank, Boston, MA (US); Ralf A6IP3L/20 (2006.01) Altmeyer, Singapore (SG) (52) U.S. Cl. ........ 514/255.03: 514/647; 435/6: 514/415; Correspondence Address: 514/460, 514/275: 514/529 CLARK & ELBNG LLP 101 FEDERAL STREET BOSTON, MA 02110 (57) ABSTRACT (21) Appl. No.: 11/900,893 The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain (22) Filed: Sep. 13, 2007 embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particu Related U.S. Application Data lar embodiments, the viral disease is viral hepatitis (e.g., (60) Provisional application No. 60/844,463, filed on Sep. hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E). 14, 2006, provisional application No. 60/874.061, Also featured are screening methods for identification of filed on Dec. 11, 2006. novel compounds that may be used to treat a viral disease.
  • Lysergic Acid Biethylamide Binds to a Novel Serotonergic Site on Rat Choroid Plexus Epithelial Cells’

    Lysergic Acid Biethylamide Binds to a Novel Serotonergic Site on Rat Choroid Plexus Epithelial Cells’

    0270.6474/85/0512-3178$02.00/O The Journal of Neuroscrence Copyrrght 0 Society for Neuroscrence Vol. 5, No. 12, pp. 3178-3183 Printed I” U S A December 1985 ‘*%Lysergic Acid Biethylamide Binds to a Novel Serotonergic Site on Rat Choroid Plexus Epithelial Cells’ KEITH A. YAGALOFF AND PAUL R. HARTIG’ Department of Biology, Johns Hopkins University, Baltimore, Maryland 2 1218 Abstract ‘251-Lysergic acid diethylamide (‘251-LSD) binds with high Materials and Methods affinity to serotonergic sites on rat choroid plexus. These Autoradrography. Coronal sections (6 to 8 pm) of frozen adult rat brains sites were localized to choroid plexus epithelial cells by use were thaw-mounted onto subbed mrcroscope slides, air-drred for 20 min, of a novel high resolution stripping film technique for light and stored at -20°C In dessrcated microscope boxes. The mounted trssue microscopic autoradiography. In membrane preparations sections were brought to room temperature and then labeled with ‘?LSD from rat choroid plexus, the serotonergic site density was bv a technique srmilar to the method of Nakada et al. (1984). Sections were 3100 fmol/mg of protein, which is lo-fold higher than the incubated for 60 min at room temperature In 50 mM Tris-HCI buffer (pH 7.6) density of any other serotonergic site in brain homogenates. containina either 1.5 nM ‘?LSD (2000 Ci/mmol) or 1.5 nM “51-LSD and 1 UM The choroid plexus site exhibits a novel pharmacology that ketansen;, to determine nonspecific binbrng. ‘?LSD was synthesized ‘by does not match the properties of 5hydroxytryptamine-la (5 the method of Morettr-Rojas et al.
  • Drug Natural Product Infection # of References Corticosteroid

    Drug Natural Product Infection # of References Corticosteroid

    Drug Natural Infection # of References Product corticosteroid yes severe acute respiratory syndrome; 32 Middle East respiratory syndrome 2 quercetin yes severe acute respiratory syndrome; 1 coronavirus infection 1 glycyrrhizin yes severe acute respiratory syndrome 11 glucocorticoid yes severe acute respiratory syndrome 5 baicalin yes severe acute respiratory syndrome 2 escin yes severe acute respiratory syndrome 2 lycorine yes severe acute respiratory syndrome 2 reserpine yes severe acute respiratory syndrome 2 sinigrin yes severe acute respiratory syndrome 2 S-nitroso-N-acetylpenicillamine yes severe acute respiratory syndrome 2 6-mercaptopurine yes severe acute respiratory syndrome 1 6-thioguanine yes severe acute respiratory syndrome 1 ginsenoside Rb1 yes severe acute respiratory syndrome 1 glycyrrhetinic acid yes severe acute respiratory syndrome 1 Glycyrrhiza glabra root yes severe acute respiratory syndrome 1 hammerhead ribozyme yes severe acute respiratory syndrome 1 heparan sulfate yes severe acute respiratory syndrome 1 hesperetin yes severe acute respiratory syndrome 1 Kampo yes severe acute respiratory syndrome 1 luteolin yes severe acute respiratory syndrome 1 mannan yes severe acute respiratory syndrome 1 miltirone yes severe acute respiratory syndrome 1 myricetin yes severe acute respiratory syndrome 1 ouabain yes coronavirus infection 1 oxymatrine yes severe acute respiratory syndrome 1 proanthocyanidins yes severe acute respiratory syndrome 1 scutellarein yes severe acute respiratory syndrome 1 secoiridoid yes severe acute
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes

    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes

    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7